MAPT and Alzheimer disease: Cross‐sectional and longitudinal studies across neurodegenerative diseases (e.g., AD, CSVD) consistently link lower ALPS indices to elevated Aβ/tau deposition and accelerated cognitive decline [52, 53, 54].